AxoGen reports Q1 adjusted EPS (6c), consensus (7c)

Reports Q1 revenue $41.4M, consensus $41.96M. “We are pleased with the positive trend in the bottom line and continue to focus on higher productivity as we grow revenue. This is in line with our goal of reaching profitability and positive cashflow as we execute on our growth strategy,” commented Karen Zaderej, chairman, CEO, and president of Axogen, Inc. “We are encouraged by our team’s performance and execution heading into key near-term milestones. We look forward to our national launch for Avive+ Soft Tissue Matrix in June, and completion of our rolling BLA submission for Avance Nerve Graft(R) in the third quarter.”